Adipogenix, Inc.

Boston, MA 02119

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $1.88MM
First Award Date 07/01/99
Most Recent Award Date 04/01/05

Key Personnel

Last Name Name Awards Contact
Brooks Cydney C Brooks 4
Waloga Geraldine Waloga 5

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/05 - 03/31/07

DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing treatments for obesity are only modestly effective. The mission of AdipoGenix, Inc. is to discover and develop novel therapeutics acting on the fat cell, an approach that is likel...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/04 - 03/31/05

DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing treatments for obesity are only modestly effective. The mission of AdipoGenix, Inc. is to discover and develop novel therapeutics acting on the fat cell, an approach that is likel...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/15/03 - 06/30/04

DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing drug and dietary treatments for obesity are only modestly effective. An approach that is very likely to be effective in treating obesity and with a good side effect profile is a d...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/03 - 08/31/03

DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Although weight loss is the most effective treatment for type 2 diabetes, current methods for reducing weight typically are insufficient for long-term weight loss. The mission of AdipoGeni...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/02 - 08/31/03

DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. While weight loss is the most effective treatment of type 2 diabetes, current methods for reducing weight are typically insufficient for long-term weight loss. The mission of AdipoGenix, I...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/02 - 02/28/03

DESCRIPTION (Scanned from the Applicant's Abstract): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Weight loss is the optimal treatment for type 2 diabetes, however current methods for reducing weight are insufficient for lon...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/01 - 02/28/02

DESCRIPTION (Scanned from the Applicant's Abstract): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Weight loss is the optimal treatment for type 2 diabetes, however current methods for reducing weight are insufficient for lon...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/00 - 12/31/01

Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. While weight loss is the most effective treatment of type 2 diabetes, current methods for reducing weight are typically insufficient for long-term weight loss. The mission of AdipoGenix, Inc. is to discover, develop, and lice...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/99 - 06/30/00